**FULL PRESCRIBING INFORMATION: CONTENTS**
**1 INDICATIONS AND USAGE**
**2 DOSAGE AND ADMINISTRATION**

2.1. Recommended Dosage
2.2. Dosage Modifications for Strong CYP3A4 Inhibitors

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

5.1. Embryo-Fetal Toxicity
5.2. QTc Interval Prolongation

**6 ADVERSE REACTIONS**

6.1 Clinical Trials Experience

**7 DRUG INTERACTIONS**

7.1. Effect of Other Drugs on XOLREMDI
7.1. Effect of XOLREMDI on Other Drugs
7.1. Drugs that Prolong the QTc Interval

**8 USE IN SPECIFIC POPULATIONS**

8.1. Pregnancy
8.2. Lactation
8.3. Females and Males of Reproductive Potential
8.4. Pediatric Use
8.5. Geriatric Use
8.6. Renal Impairment
8.7. Hepatic Impairment ![](Aspose.Words.c0d57741-1e92-457a-a6ee-a45779083e95.002.png)

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

12.1. Mechanism of Action
12.2. Pharmacodynamics
12.3. Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES**

**16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

Reference ID: 5371673
